276 related articles for article (PubMed ID: 29454659)
1. Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration.
Rohm M; Tresp V; Müller M; Kern C; Manakov I; Weiss M; Sim DA; Priglinger S; Keane PA; Kortuem K
Ophthalmology; 2018 Jul; 125(7):1028-1036. PubMed ID: 29454659
[TBL] [Abstract][Full Text] [Related]
2. Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning.
Chandra RS; Ying GS
Ophthalmol Retina; 2024 May; 8(5):419-430. PubMed ID: 38008218
[TBL] [Abstract][Full Text] [Related]
3. Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration.
Nguyen V; Daien V; Guymer R; Young S; Hunyor A; Fraser-Bell S; Hunt A; Gillies MC; Barthelmes D;
Ophthalmology; 2019 Jan; 126(1):64-74. PubMed ID: 30149035
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration.
Stem MS; Moinuddin O; Kline N; Thanos A; Rao P; Williams GA; Hassan TS
JAMA Ophthalmol; 2018 Jul; 136(7):820-823. PubMed ID: 29800991
[TBL] [Abstract][Full Text] [Related]
5. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
[TBL] [Abstract][Full Text] [Related]
6. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
7. Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning.
Fu DJ; Faes L; Wagner SK; Moraes G; Chopra R; Patel PJ; Balaskas K; Keenan TDL; Bachmann LM; Keane PA
Ophthalmol Retina; 2021 Nov; 5(11):1074-1084. PubMed ID: 33516917
[TBL] [Abstract][Full Text] [Related]
8. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
9. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
10. Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
Keenan TD; Vitale S; Agrón E; Domalpally A; Antoszyk AN; Elman MJ; Clemons TE; Chew EY;
Ophthalmol Retina; 2020 Jan; 4(1):3-12. PubMed ID: 31395505
[TBL] [Abstract][Full Text] [Related]
11. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
12. Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Hsu J; Patel SN; Wolfe JD; Shah CP; Chen E; Jenkins TL; Wibbelsman TD; Obeid A; Mikhail M; Garg SJ; Ho AC; Chiang A; Spirn MJ; Vander JF
JAMA Ophthalmol; 2020 May; 138(5):560-567. PubMed ID: 32239190
[TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
14. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort.
Gillies MC; Walton RJ; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Barthelmes D
Ophthalmology; 2014 Mar; 121(3):676-81. PubMed ID: 24290801
[TBL] [Abstract][Full Text] [Related]
15. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
16. Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: Data from a real-world clinical setting.
Fulcher C; Hazel CA; Pacey I; Ali H; Ghanchi FD
Eur J Ophthalmol; 2020 May; 30(3):543-549. PubMed ID: 30935224
[TBL] [Abstract][Full Text] [Related]
17. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Campain A; Barthelmes D; Simpson JM; Arnold JJ; Guymer RH; McAllister IL; Essex RW; Morlet N; Hunyor AP;
Ophthalmology; 2015 Sep; 122(9):1837-45. PubMed ID: 26096346
[TBL] [Abstract][Full Text] [Related]
19. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
20. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
